Delving into the Latest Updates on PARKSIDE SCIENTIFIC INC with Synapse

Overview

Tags

Neoplasms

Other Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	2

Top 5 Target	Count

BRDT(bromodomain testis associated)	1

主要目的：评价JL1132治疗复发/难治性血液肿瘤的耐受性和安全性，探索最大耐受剂量（MTD），以及II期临床推荐剂量（RP2D）。次要目的：评价JL1132在复发/难治性血液肿瘤患者的药代动力学（PK）特征及药效学（PD）特征；评价JL1132治疗复发/难治性血液肿瘤的有效性。

[Translation]

Primary objective: To evaluate the tolerability and safety of JL1132 in the treatment of relapsed/refractory hematological malignancies, and to explore the maximum tolerated dose (MTD) and the recommended dose (RP2D) for Phase II clinical trials. Secondary objective: To evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of JL1132 in patients with relapsed/refractory hematological malignancies; to evaluate the effectiveness of JL1132 in the treatment of relapsed/refractory hematological malignancies.

Start Date-

Sponsor / Collaborator

Jilin Jianglin Biotechnology Co., Ltd.

[+1]

100 Clinical Results associated with PARKSIDE SCIENTIFIC INC

Login to view more data

0 Patents (Medical) associated with PARKSIDE SCIENTIFIC INC

Login to view more data

100 Deals associated with PARKSIDE SCIENTIFIC INC

Login to view more data

100 Translational Medicine associated with PARKSIDE SCIENTIFIC INC

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Oct 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

2

Login to view more data